Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2025-05-01 Annual Report
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
20F For the fiscal year ended December 31, 2024
Annual Report Classification · 1% confidence The document is explicitly titled 'FORM 20-F' and identified as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2024. Form 20-F is the standard annual report filing for foreign private issuers with the U.S. SEC, which corresponds to the 10-K category in the provided schema. FY 2024
2025-05-01 English
20F For the fiscal year ended December 31, 2024
Report Publication Announcement Classification · 1% confidence The document explicitly states it is a 'Report of Periodic or Interim Report' under Israeli Securities Authority regulations. It mentions an attached file named '*20F30042025_isa.pdf*'. The Form 20-F is the standard annual report filed by foreign private issuers with the SEC, which aligns closely with the comprehensive nature of an Annual Report (10-K) for foreign entities, or potentially an Interim Report if the context implied a shorter period, but 20-F is typically annual. However, the document itself is very short (1882 characters) and functions primarily as a cover page or notification stating that the actual report ('*20F30042025_isa.pdf*') is attached or referenced. According to Rule 2, if the document is short and announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). Given the context of a foreign issuer filing a 20-F (which is an annual filing), the most appropriate primary classification for the *actual report* would be 10-K (Annual Report). However, since this text is merely the *announcement* of the filing, RPA is the correct classification based on the provided rules.
2025-05-01 English
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing used by Foreign Private Issuers to report material information to the SEC, often mirroring the content of a press release. The content itself is a press release announcing that the company will present poster abstracts at a medical conference (OARSI 2025 World Congress). Since this is a formal SEC filing (Form 6-K) containing material, non-public information (or information that would typically be released via press release), it is a regulatory filing. While it contains information about presentations, the primary document type is the SEC filing itself. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for an SEC Form 6-K that doesn't fit a more specific category like 10-K or DEF 14A. However, since the content is essentially an announcement of participation in a scientific congress, and it is filed on Form 6-K (which is often used for miscellaneous material events), RNS serves as the best fit among the provided codes for a non-standard, periodic SEC report.
2025-04-23 English
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k23042025_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The presence of ISA and TASE headers suggests it's a regulatory filing, but the primary function here is announcing the attached 6-K report.
2025-04-23 English
Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," filed on Form 6-K for the month of April 2025. Form 6-K filings are used by foreign private issuers to report material information to the SEC, often mirroring the content of a press release or other material event disclosure in their home jurisdiction. The content itself is a press release announcing the completion of patient enrollment in a Phase II clinical trial stage. While it contains financial/operational news, the primary regulatory filing type indicated by the header is the Form 6-K. Among the provided classification codes, there is no direct match for Form 6-K. However, Form 6-K is a mandatory periodic/current report for foreign private issuers, similar in function to other required SEC filings. Given the options, this document is a regulatory filing that announces material information. Since it is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a specific announcement like DIV or DIRS, the most appropriate fallback category for a general, material SEC filing that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as Form 6-K is a standard regulatory submission. Alternatively, since the core content is an announcement of clinical trial progress, it could be argued as an Investor Presentation (IP) or a general announcement, but the structure is definitively that of an SEC filing (Form 6-K). RNS is the best fit for a non-standard SEC form that isn't covered by the other specific codes.
2025-04-21 English
Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
Report Publication Announcement Classification · 1% confidence The document is extremely short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k21042025_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The presence of the Israel Securities Authority and Tel Aviv Stock Exchange context suggests it is a regulatory filing, but the primary action described is the publication/attachment of the main report, fitting RPA best. If RPA were not an option, RNS would be considered, but RPA is more specific to announcing the release of a report.
2025-04-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.